Levels of brain-derived neurotrophic factor in patients with multiple sclerosis.
- Naegelin Y Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, 4031, Switzerland.
- Saeuberli K School of Biosciences, Cardiff University, Cardiff, CF10 3AX, United Kingdom.
- Schaedelin S Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, Basel, 4031, Switzerland.
- Dingsdale H School of Biosciences, Cardiff University, Cardiff, CF10 3AX, United Kingdom.
- Magon S Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, 4031, Switzerland.
- Baranzini S Department of Neurology, University of California, San Francisco, San Francisco, CA, 94158, USA.
- Amann M Medical Image Analysis Center (MIAC) AG, Basel, 4051, Switzerland.
- Parmar K Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, 4031, Switzerland.
- Tsagkas C Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, 4031, Switzerland.
- Calabrese P Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, 4031, Switzerland.
- Penner IK Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, 40225, Germany.
- Kappos L Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, 4031, Switzerland.
- Barde YA School of Biosciences, Cardiff University, Cardiff, CF10 3AX, United Kingdom.
- 2020-10-08
Published in:
- Annals of clinical and translational neurology. - 2020
English
OBJECTIVE
To determine the levels of brain-derived neurotrophic factor (BDNF) in the serum of patients suffering from multiple sclerosis (MS) to evaluate the potential of serum BDNF as a biomarker for MS.
METHODS
Using a recently validated enzyme-linked immunoassay (ELISA) we measured BDNF in patients with MS (pwMS), diagnosed according to the 2001 McDonald criteria and aged between 18 and 70 years, participating in a long-term cohort study with annual clinical visits, including blood sampling, neuropsychological testing, and brain magnetic resonance imaging (MRI). The results were compared with an age- and sex-matched cohort of healthy controls (HC). Correlations between BDNF levels and a range of clinical and magnetic resonance imaging variables were assessed using an adjusted linear model.
RESULTS
In total, 259 pwMS and 259 HC were included, with a mean age of 44.42 ± 11.06 and 44.31 ± 11.26 years respectively. Eleven had a clinically isolated syndrome (CIS), 178 relapsing remitting MS (RRMS), 56 secondary progressive MS (SPMS), and 14 primary progressive MS (PPMS). Compared with controls, mean BDNF levels were lower by 8 % (p˂0.001) in pwMS. The level of BDNF in patients with SPMS was lower than in RRMS (p = 0.004).
INTERPRETATION
We conclude that while the use of comparatively large cohorts enables the detection of a significant difference in BDNF levels between pwMS and HC, the difference is small and unlikely to usefully inform decision-making processes at an individual patient level.
To determine the levels of brain-derived neurotrophic factor (BDNF) in the serum of patients suffering from multiple sclerosis (MS) to evaluate the potential of serum BDNF as a biomarker for MS.
METHODS
Using a recently validated enzyme-linked immunoassay (ELISA) we measured BDNF in patients with MS (pwMS), diagnosed according to the 2001 McDonald criteria and aged between 18 and 70 years, participating in a long-term cohort study with annual clinical visits, including blood sampling, neuropsychological testing, and brain magnetic resonance imaging (MRI). The results were compared with an age- and sex-matched cohort of healthy controls (HC). Correlations between BDNF levels and a range of clinical and magnetic resonance imaging variables were assessed using an adjusted linear model.
RESULTS
In total, 259 pwMS and 259 HC were included, with a mean age of 44.42 ± 11.06 and 44.31 ± 11.26 years respectively. Eleven had a clinically isolated syndrome (CIS), 178 relapsing remitting MS (RRMS), 56 secondary progressive MS (SPMS), and 14 primary progressive MS (PPMS). Compared with controls, mean BDNF levels were lower by 8 % (p˂0.001) in pwMS. The level of BDNF in patients with SPMS was lower than in RRMS (p = 0.004).
INTERPRETATION
We conclude that while the use of comparatively large cohorts enables the detection of a significant difference in BDNF levels between pwMS and HC, the difference is small and unlikely to usefully inform decision-making processes at an individual patient level.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1002/acn3.51215
- PMID 33031634
- Persistent URL
- https://sonar.ch/global/documents/139347
Statistics
Document views: 33
File downloads:
- Full-text: 0